Performing Cost-Effectiveness Analysis by Integrating Randomized Trial Data with a Comprehensive Decision Model
Gregory P. Samsa, Richard A. Reutter, Giovanni Parmigiani et al. · Journal of Clinical Epidemiology · 1999
Cited by 140 works. doi:10.1016/s0895-4356(98)00151-6
Authors
- Gregory P. Samsa
- Richard A. Reutter
- Giovanni Parmigiani
- Marek Ancukiewicz
- Paul H. Abrahamse
- Joseph Lipscomb
- David Bruce Matchar
References
- Tissue Plasminogen Activator for Acute Ischemic Stroke
- Cost-Effectiveness in Health and Medicine
- Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
- How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.
- Recovery of motor function after stroke.
- Costs, effects and C/E‐ratios alongside a clinical trial
- The hemiplegic arm after stroke: measurement and recovery.
- Multi-Attribute Health Status Classification Systems
- Recovery after stroke
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial Infarction